The Pharma Letter47m
hVIVO plans challenge trial for RSV antiviral candidate
UK contract research organization hVIVO (AIM: HVO) is gearing up to test an inhaled antiviral candidate, IN-002, for ...
The Pharma Letter49m
FDA approves Celltrion's Avtozma, a biosimilar to Actemra
The US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to Actemra, developed by South ...
The Pharma Letter53m
Sweden’s annual life science conference highlights need for action
At Sweden’s annual life science conference, stakeholders from healthcare, academia, and industry discussed implementing the ...
The Pharma Letter57m
EFPIA response to the EC’s ‘Competitiveness Compass’
The European Federation of Industries and Associations (EFPIA) has welcomed the publication of the Competitiveness Compass ...
The Pharma Letter1h
BRIEF—EC calls for update on regulatory review of lecanemab
Japan’s Eisai and US partner Biogen have announced today update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab (trade name Leqembi) as a treatment for early ...
The Pharma Letter23h
The week in pharma: action, reaction and insight – week to January 31
Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria ...